Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The document concludes that inflammation markers can be used in diabetes, vitamin D3 affects immune pathways, hyperthyroidism changes hormone levels, androgen levels help diagnose Adrenocortical Carcinoma, erectile dysfunction is linked to diabetes, hypogonadism is common in HIV-infected males, and hormones can be biomarkers for various conditions.

Skin pigmentation varies due to genetics, UV exposure, and drugs, with treatments available but requiring medical advice.

Hormones like testosterone and estrogen significantly affect hair growth and structure.

Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.

The conclusion is that women under 35 should start fertility checks after 12 months of trying to conceive, women over 35 after 6 months, and women over 40 should start immediately. The checks should include ovulation status, reproductive tract structure, and male partner's semen evaluation.

The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.

Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.

Insulin resistance and high male hormone levels are major causes of Polycystic Ovary Syndrome.

Understanding sex and gender differences can improve personalized dermatology care.

Genetic variations greatly affect individual metabolism and can impact health and disease risk.

Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.

Targeting specific molecular pathways may improve treatments for chemoresistant cancers.

Nonhuman primates are valuable in research but their natural health variations can complicate study results.

The link between anabolic agents and colorectal cancer risk is unclear.

The article suggests renaming Polycystic Ovarian Syndrome (PCOS) to "Hyperandrogenic Persistent Ovulatory Dysfunction Syndrome" (HA-PODS) for accuracy and consistency, but no final decision was made.

About 19.4% of Iranian women in the study have Polycystic Ovary Syndrome, with the most common type involving irregular periods and high male hormone levels, but their heart and metabolic health is similar to women without the condition.

Testosterone therapy is effective and safe for women with low sexual desire, but it's hard to access.

Common skin conditions can greatly affect a person's mental health and social life.

Severe menstrual issues in PCOS women signal higher risk for heart and metabolic problems.

Natural products may help treat Non-Small Cell Lung Cancer by causing cancer cell death through ferroptosis.

The 2023 guideline for PCOS suggests using updated diagnostic criteria, assessing related health risks, and recommends lifestyle changes and specific treatments for symptoms and fertility issues.

The 2023 guideline advises a detailed approach for PCOS, focusing on early detection, lifestyle and medical treatments, and managing health risks.

The guidelines standardize mesotherapy practices for safety and effectiveness in pain, rehabilitation, and skin treatments.

Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.

Adult female acne is complex and requires a combination of treatments for effective management.

SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.

Lower adiponectin levels are linked to higher insulin resistance in women with PCOS.

Obesity leads to physical, metabolic, reproductive issues, higher healthcare costs, and mental health problems.

The study found that PCOS affects about 6.5-6.8% of women in both urban and rural areas of Telangana, India, and highlighted the importance of lifestyle changes for management.

SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.